Literature DB >> 21067945

Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy.

Sang-Ahm Lee1, Hyang-Woon Lee, Kyoung Heo, Dong-Jin Shin, Hong-Ki Song, Ok-Joon Kim, Sun-Mi Lee, Seon-Ok Kim, Byung-In Lee.   

Abstract

PURPOSE: In this prospective study, we compared the long-term cognitive and behavioral effects of lamotrigine (LTG) and carbamazepine (CBZ) in patients with newly diagnosed or untreated partial epilepsy.
METHODS: This was a multicenter, open-label, randomized study that compared monotherapy with LTG and CBZ in newly diagnosed or untreated patients with partial epilepsy. We employed an 8-week titration period and a 40-week maintenance period. Neuropsychological tests, Symptom Check List-90, and QOLIE-31 were assessed at baseline, 16 weeks, and 48 weeks after drug treatment. A group-by-time interaction was the primary outcome measure and was analyzed by use of the linear mixed model.
RESULTS: A total of 110 patients were eligible and 73 completed the 48-week study (LTG, n=39; CBZ, n=34). Among the cognitive tests, significant group-by-time interaction was identified only in phonemic fluency of Controlled Oral Word Association Task (p=0.0032) and Stroop Color-Word Interference (p=0.0283), with a significant better performance for LTG group. All other neuropsychological tests included did not show significant group-by-time interactions. Among the subscales of Symptom Check List-90, significant group-by-time interactions were identified in Obsessive-Compulsive (p=0.0005), Paranoid Ideation (p=0.0454), Global Severity Index (p=0.0194), and Positive Symptom Total (p=0.0197), with a significant improvement for CBZ group. QOLIE-31 did not show significant group-by-time interactions.
CONCLUSION: Our data suggest that epilepsy patients on LTG have better performance on phonemic fluency and the task of Stroop Color-Word Interference than do patients on CBZ, whereas patients on CBZ had more favorable behavioral effects on two subscales and two global scores of Symptom Check List-90 than did patients on LTG. Copyright Â
© 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21067945     DOI: 10.1016/j.seizure.2010.10.006

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  10 in total

1.  The cognitive impact of antiepileptic drugs.

Authors:  Clare M Eddy; Hugh E Rickards; Andrea E Cavanna
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

Review 2.  Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.

Authors:  Sarah J Nevitt; Maria Sudell; Jennifer Weston; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2017-06-29

Review 3.  Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nolan; Catrin Tudur Smith; Jennifer Weston; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2016-11-14

Review 4.  Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.

Authors:  Sarah J Nevitt; Maria Sudell; Sofia Cividini; Anthony G Marson; Catrin Tudur Smith
Journal:  Cochrane Database Syst Rev       Date:  2022-04-01

5.  Brivaracetam and Levetiracetam Suppress Astroglial L-Glutamate Release through Hemichannel via Inhibition of Synaptic Vesicle Protein.

Authors:  Kouji Fukuyama; Motohiro Okada
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

Review 6.  Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nevitt; Catrin Tudur Smith; Jennifer Weston; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2018-06-28

7.  Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications.

Authors:  Alejandro Szmulewicz; Cecilia Samamé; Pablo Caravotta; Diego J Martino; Ana Igoa; Diego Hidalgo-Mazzei; Francesc Colom; Sergio A Strejilevich
Journal:  Int J Bipolar Disord       Date:  2016-02-16

Review 8.  Cognitive Impairment in People with Epilepsy.

Authors:  Ajda Novak; Karmen Vizjak; Martin Rakusa
Journal:  J Clin Med       Date:  2022-01-05       Impact factor: 4.241

Review 9.  Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.

Authors:  Adam Strzelczyk; Susanne Schubert-Bast
Journal:  CNS Drugs       Date:  2022-10-04       Impact factor: 6.497

Review 10.  Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.

Authors:  Sarah J Nevitt; Maria Sudell; Jennifer Weston; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2017-12-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.